Drug intelligence / Profile preview

EC-R214

Development stage: Preclinical
Lead developer: ExoCan Healthcare Technologies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

EC-R214 is an mRNA-based therapeutic candidate currently in early-stage development by ExoCan Healthcare Technologies. The program is focused on applications within the field of immunology. ExoCan Healthcare Technologies specializes in exosome-based drug delivery and bio-diagnostics; EC-R214 likely utilizes the company's proprietary exosome platform to deliver mRNA payloads designed to modulate immune responses. As of 2024, the specific molecular target, the exact immunological indication, and the clinical development phase have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on EC-R214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC-R214.

Explore the full profile